Multinational pharmaceutical companies deploy domestic market | Sanofi asthma treatment drug is expected to be listed this year
According to the medical network on May 3, asthma is recognized by the world medical community as one of the four chronic diseases, and is the second most common cause of death and disability in the world after cancer. It is due to allergies, circulatory system or congestion of the lungs, and bronchial edema. Respiratory diseases caused by various causes such as kidney or heart disease and central nervous system excitement. According to WHO estimates, asthma patients will increase to 400 million by 2025. Our asthma patients have also been less than 20 million people from 10 years ago. Increased to 30 million, and the morbidity and mortality have been showing an upward trend, with multiple children.
Tertiary hospitals dominate the market, outpatient and emergency services are the main channels for patients
According to the RAS data from the China National Pharmaceutical Industry Information Center, the amount of prescription prescriptions for asthma in 2017 accounted for 4.40% of total prescriptions, and achieved an increase of 2.30%.
As morbidity and mortality continue to rise, asthma is a serious threat to the public globally. health The domestic asthma drug application market is mainly concentrated in second- and third-tier hospitals; because of the high difficulty of asthma treatment, tertiary hospitals occupy the absolute market.
Source: Hospital Prescription Analysis System (RAS)
At the same time, due to the characteristics of asthma, outpatient and emergency services are the main channels for patients. At present, the use of asthma drugs is mainly concentrated in respiratory medicine clinics, general outpatient clinics for children, respiratory medicine wards, etc. It is worth noting that asthma is common in childhood. Chronic disease, and the incidence of children is 2-3 times that of adults. If not actively treated, about 1/3 to 1/2 of children's asthma can be delayed to adults.
Source: Hospital Prescription Analysis System (RAS)
Looking at the domestic market, with foreign brands as the dominant factor, multinational pharmaceutical giants compete to layout
China's asthma medication is dominated by Western medicine; more dominated by foreign brand drugs, multinational pharmaceutical giants want to further sweep the Chinese market.
At present, the main manufacturers of asthma drugs in the domestic market are AstraZeneca and GlaxoSmithKline. The two companies occupy most of the market. In fact, the two markets are in a similar situation, but the single products have their own advantages. In the aerosol market, GlaxoSmithKline The predominance of grams, and the oral tablet market, was dominated by Merck and AstraZeneca. The respiratory drug Benralizumab developed by AstraZeneca has a unique mode of action in eosinophilic phenotypic patients with severe asthma and can significantly reduce asthma. Attacks, improve lung function and symptoms, and fewer medications per year.
Source: Hospital Prescription Analysis System (RAS)
Sanofi is Expected to Be Listed This Year for Severe Asthma Treatment Drug Dupixent
From the prescription data, we observed that asthma drugs are concentrated in three types of drugs: respiratory drugs, anti-infectives and Chinese medicines. Among them, the proportion of respiratory drugs has broken through from 58.57% in 2016 to 61.19% in 2017. The proportion of infectious drugs dropped from 18.86% in 2016 to 15.85% in 2017. The proportion of Chinese medicines was relatively flat, and the overall drug concentration was further improved.
Source: Hospital Prescription Analysis System (RAS)
In clinical application, asthma treatment drugs are mainly chemical drugs. Drugs for the treatment of asthma can be divided into control drugs and palliative drugs: Control drugs refer to drugs that need to be used daily for a long time, and control drugs mainly maintain clinical control of asthma through anti-inflammatory effects; Relief medication refers to medications that are used on demand. Relieving medications relieves asthma symptoms by rapidly releasing bronchospasm.
In recent years, with the deterioration of the global air and environment, the incidence of asthma and mortality have increased year by year, and asthma has been difficult to cure, and the treatment cycle is long. As a result, sales of anti-asthma drugs nationwide have increased rapidly. Montelukast sodium As a control drug for the treatment of asthma, it is a highly selective leukotriene CysLT1 (LTD4) receptor antagonist, which can significantly improve the inflammatory index and has a significant effect on asthma patients. The drug is easy to take, Adverse reactions The advantages of small size have become a new generation in the treatment of chronic asthma. drug Among the domestic anti-asthma drugs, the approved leukotriene receptor antagonist products are only montelukast sodium and zalusite, of which montelukast sodium predominates. medicine Industrial Information Center Medical Prescription Drug System Data Display, 2017 Domestic Samples hospital The market share of montelukast sodium in anti-asthma drugs reached 11.98%, an increase of 11.53% over the same period of last year, ranking second in the market share of anti-asthma drugs.
Source: Hospital Prescription Analysis System (RAS)
On a global scale, the compound annual growth rate of the respiratory medicine market is about 0.6%, and the market share will exceed 27 billion US dollars by 2015. In China, its overall market capacity is also increasing year by year, and the increase rate is faster than that of the pharmaceutical industry. This phenomenon also makes the respiratory medicine market appear to be characterized by large capacity and rapid growth. Haze also turns the respiratory medicine market into a tempting giant cake, which has brought about a high rate of morbidity. The market’s prospects are that respiratory drug use is considered to be one of the most promising drug markets in the future, and that asthma medicines account for half of the respiratory drug use. It is also a huge market for international pharmaceutical giants to compete for seats, but the market is in China. Without being fully activated, there is still market space to tap.
This year, Sanofi announced that the FDA has accepted Dupixent's supplemental biopharmaceutical marketing licensing application. This new drug is expected to be marketed this year as an additional maintenance therapy for some moderate to severe adults and asthmatic patients 12 years of age and older. We also hope that with the The continuous emergence of new drugs on the market really brings more gospels for patients to improve treatment and even cure the disease.
